Clinical Trial Update: A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 clinical study evaluating the CD70-targeted agent CHT101 in relapsed or refractory hematologic malignancies is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Non-hodgkin Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• CHT101 (CHT101)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma (CTCL) | Phase 1 | Status: RECRUITING